Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

[Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].

Lü Y, Yan Z, Wang DH, Dong WL, Yang Y, Xia R.

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013 Aug;25(8):479-83. doi: 10.3760/cma.j.issn.2095-4352.2013.08.008. Chinese.

2.

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.

Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I.

Curr Med Res Opin. 2008 Jul;24(7):2113-26. doi: 10.1185/03007990802179255 . Epub 2008 Jun 11.

PMID:
18549664
3.

Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.

Bao H, Lv Y, Wang D, Xue J, Yan Z.

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):459-466. doi: 10.1007/s10096-016-2819-1. Epub 2016 Oct 28.

4.

Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP.

Antimicrob Agents Chemother. 2012 Aug;56(8):4087-94. doi: 10.1128/AAC.00521-12. Epub 2012 May 14.

5.

Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.

Arnold HM, Hollands JM, Skrupky LP, Smith JR, Juang PH, Hampton NB, McCormick S, Reichley RM, Hoban A, Hoffmann J, Micek ST, Kollef MH.

Ann Pharmacother. 2013 Feb;47(2):170-80. doi: 10.1345/aph.1R523. Epub 2013 Jan 22.

PMID:
23341160
6.

Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs.

Duszynska W, Taccone FS, Switala M, Hurkacz M, Kowalska-Krochmal B, Kübler A.

Int J Antimicrob Agents. 2012 Feb;39(2):153-8. doi: 10.1016/j.ijantimicag.2011.10.011. Epub 2011 Dec 9.

PMID:
22154855
7.

Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.

Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.

Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.

PMID:
19809009
9.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

PMID:
17205441
10.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group..

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
11.

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Kim A, Sutherland CA, Kuti JL, Nicolau DP.

Pharmacotherapy. 2007 Nov;27(11):1490-7.

PMID:
17963458
12.

Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.

Cies JJ, Shankar V, Schlichting C, Kuti JL.

Pediatr Infect Dis J. 2014 Feb;33(2):168-73. doi: 10.1097/INF.0b013e3182a743c7.

PMID:
23907263
13.

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP.

Antimicrob Agents Chemother. 2012 Jan;56(1):544-9. doi: 10.1128/AAC.01752-10. Epub 2011 Nov 7.

14.

Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.

Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2002 May;22(5):569-77.

PMID:
12013355
15.

Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.

Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.

Pharmacotherapy. 2014 Jan;34(1):28-35. doi: 10.1002/phar.1324. Epub 2013 Jul 17.

PMID:
23864417
16.

Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.

Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.

J Antimicrob Chemother. 2014 Jan;69(1):176-9. doi: 10.1093/jac/dkt300. Epub 2013 Jul 18.

PMID:
23869050
17.

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.

Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B.

Intensive Care Med. 2004 May;30(5):976-9. Epub 2004 Apr 1.

PMID:
15057512
18.

Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.

Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, Maraví-Poma E, Torres-Martí A, Nava J, Martínez-Pellús A, Palomar M, Barcenilla F; Spanish Collaborative Group for the Study of Severe Infections..

Intensive Care Med. 2001 Mar;27(3):493-502.

PMID:
11355117
19.

Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

Patel N, Scheetz MH, Drusano GL, Lodise TP.

Antimicrob Agents Chemother. 2010 Jan;54(1):460-5. doi: 10.1128/AAC.00296-09. Epub 2009 Oct 26.

20.

Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML.

Int J Antimicrob Agents. 2009 May;33(5):464-8. doi: 10.1016/j.ijantimicag.2008.10.025. Epub 2009 Jan 15.

PMID:
19150225

Supplemental Content

Support Center